Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 2:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC) Clear all

Recruiting No phase listed Observational

A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection

NCT06746883

View directory record Official record

Conditions: Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Interventions: Non-interventional; Other
Lead sponsor: Innoviva Specialty Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Kansas City, Kansas • Lexington, Kentucky • New Orleans, Louisiana + 5 more

Source: ClinicalTrials.gov public record

Updated Feb 24, 2026 · Synced May 22, 2026, 2:49 AM EDT

Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

NCT03894046

View directory record Official record

Conditions: Acinetobacter Baumannii-calcoaceticus Complex, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Colistin Resistant ABC
Interventions: Sulbactam, Durlobactam, Colistin, Imipenem/Cilastatin 500 mg/500 mg; Drug
Lead sponsor: Entasis Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Chicago, Illinois • Shreveport, Louisiana • Cincinnati, Ohio + 2 more

Source: ClinicalTrials.gov public record

Updated Jan 31, 2023 · Synced May 22, 2026, 2:49 AM EDT

Recruiting Phase 1 Interventional

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

NCT06801223

View directory record Official record

Conditions: Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Interventions: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours); Drug
Lead sponsor: Innoviva Specialty Therapeutics; Industry
Eligibility: 1 Day to 18 Years

Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • San Diego, California • Greenville, North Carolina + 1 more

Source: ClinicalTrials.gov public record

Updated Mar 2, 2026 · Synced May 22, 2026, 2:49 AM EDT